title: Reduced function of CD4+25+ regulatory T cell fraction in silicosis patients.
abstract: The quality and quantity of CD4+25+ regulatory T cells (Treg) in silicosis patients (SIL) were examined and compared with results from healthy donors (HD) because SIL often develop autoimmune diseases along with pulmonary disorders. Peripheral blood mononuclear cells from 57 SIL and 50 HD were analyzed for Treg. Treg frequency and clinical parameters were subjected to a factor analysis. Treg and CD4+25- T cells (Tneg) from five HD and five SIL, sorted by flow-cytometer, were used for functional assays of Treg, the expression pattern of Treg specific genes (FoxP3, GITR and CTLA-4) and activation-related genes (CD122 and CD123). Although the actual frequency of Treg did not differ between SIL and HD, the age-corrected level was reduced in SIL. The factor analysis showed that Treg frequency was positively associated with the serum level of IL-2. The inhibitory effect of Treg on Tneg activation was decreased when the Treg:Tneg ratio was 1:1/4 to 1/2. In addition, Treg dominancy of FoxP3 and CTLA-4 expression and Tneg dominancy of CD132 expression found in HD were lost in SIL. These results indicated that the Treg fraction in SIL may be substituted with chronically activated T cells due to recurrent exposure to silica, resulting in a reduction in the frequency and function of Treg. Since the reduction of Treg may precede the clinical manifestation, as silicosis may be a pre-clinical status for autoimmune diseases, control of Treg function using cell and/or gene therapy may be a good way to manage autoimmune disease.
authors.affiliation: Department of Hygiene, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan.
authors.forename: P
authors.initials: P
authors.lastname: Wu
authors.forename: Y
authors.initials: Y
authors.lastname: Miura
authors.forename: F
authors.initials: F
authors.lastname: Hyodoh
authors.forename: Y
authors.initials: Y
authors.lastname: Nishimura
authors.forename: T
authors.initials: T
authors.lastname: Hatayama
authors.forename: S
authors.initials: S
authors.lastname: Hatada
authors.forename: H
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: M
authors.initials: M
authors.lastname: Kusaka
authors.forename: H
authors.initials: H
authors.lastname: Katsuyama
authors.forename: M
authors.initials: M
authors.lastname: Tomita
authors.forename: T
authors.initials: T
authors.lastname: Otsuki
mesh_terms: D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D017209:Apoptosis / Q000276:immunology; D001327:Autoimmune Diseases / Q000209:etiology / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D005163:Factor Analysis, Statistical; D005260:Female; D015870:Gene Expression / Q000502:physiology; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology; D008297:Male; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D015398:Signal Transduction / Q000502:physiology; D012829:Silicosis / Q000235:genetics / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D019014:fas Receptor / Q000276:immunology
chemical_list: D000974:Antibodies, Antinuclear; D018076:DNA, Complementary; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D019014:fas Receptor